- Home
- CURV vs AGEN Comparison
CURV vs AGEN Comparison
Compare CURV & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURV | AGEN |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | United States | United States |
| Employees | 7590 | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.0M | 126.2M |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CURV | AGEN |
|---|---|---|
| Price | $1.25 | $3.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $1.59 | ★ $14.50 |
| AVG Volume (30 Days) | 204.2K | ★ 372.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.36 | N/A |
| EPS | 0.01 | ★ 0.37 |
| Revenue | ★ $1,103,737,000.00 | $42,877,086.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | N/A | $68.25 |
| P/E Ratio | $125.00 | ★ $8.05 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $0.94 | $1.38 |
| 52 Week High | $6.95 | $7.34 |
Technical Indicators
Market Signals| Indicator | CURV | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 48.05 |
| Support Level | $0.96 | $2.92 |
| Resistance Level | $1.41 | $3.15 |
| Average True Range (ATR) | 0.09 | 0.19 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 74.28 | 29.69 |
Price Performance
Historical ComparisonAbout CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).